Researchers pinpoint peptide that blocks hepatitis C virus entry

August 1, 2012

(Medical Xpress) -- Researchers at the University of Pittsburgh’s Graduate School of Public Health (GSPH) have identified a specific peptide that may block the entry of the hepatitis C virus (HCV) into the liver, representing a potential target for new drug development.

The results are available online now and will be published in the August 2012 print edition of Hepatology, the official journal of the American Association for the Study of Liver Disease.

“Viral entry is a multi-step process, involving a number of host factors; therefore, these findings represent a promising target for new antiviral drugs,” said Tianyi Wang, Ph.D., associate professor, Department of Infectious Diseases and Microbiology, GSPH, and the study’s lead author.

Previous research indicates that human apolipoprotein E (apoE), which occurs naturally in the body, forms complexes with HCV, the scientists said. They constructed peptides, dubbed hEP, containing the portions of apoE to which other proteins and lipids typically bind.

In lab tests, they found that hEP blocked the virus from binding to liver cells, preventing infection. That suggests apoE is involved with HCV’s initial entry into the cells, Dr. Wang said. It’s possible that hEP thwarts infection because it competes with HCV for a cell surface receptor.

In addition, researchers determined that the ability of hEP to block the virus appears to be dependent on the peptide’s length and sequence. Shorter versions could not stop infection, possibly because the shape of the proteins—and thus their binding ability—was altered.

“Our findings highlight the potential of developing peptides that mimic hEP as new viral inhibitors,” said Dr. Wang.

Worldwide, more than 170 million people are infected with the hepatitis C virus, which often is asymptomatic and can cause severe liver disease and liver cancer. There is no cure for HCV and no vaccine. Existing treatments are effective in only 40 percent to 80 percent of patients and can cause severe side effects.

Despite the recent U.S. Food and Drug Administration approval of two new antiviral drugs designed to treat chronic HCV infection, patients may rapidly develop resistance. Much like current HIV therapies, successful treatment of HCV may involve multiple inhibitors of different targets, researchers said.

“New antiviral drugs are urgently needed to treat HCV infection independently, or in combination with current therapies,” said Dr. Wang.

Collaborators on the studies include Shufeng Liu, Ph.D., and Kevin D. McCormick, M.S., Department of Infectious Diseases and Microbiology, GSPH, University of Pittsburgh; Wentao Zhao, Ph.D., and Daping Fan, Ph.D., Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina; and Ting Zhao, Department of Pathology, University of Pittsburgh School of Medicine.

Explore further: Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation

Related Stories

Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation

December 1, 2011
German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells. Study findings available in the December issue ...

University launches iphone app for hepatitis treatment

November 22, 2011
The University of Liverpool has launched an iphone app, HEP i-chart, that provides Hepatitis C (HCV) patients with quick and easy access to the latest information about drug interactions.

Researchers identify potential new therapy approach for hepatitis C

January 16, 2012
Researchers at the University of British Columbia have found a new way to block infection from the hepatitis C virus (HCV) in the liver that could lead to new therapies for those affected by this and other infectious diseases.

New vaccine for hepatitis C virus

July 28, 2011
Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

Entry point for hepatitis C infection identified

January 24, 2012
A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of ...

Recommended for you

New compound stops progressive kidney disease in its tracks

December 7, 2017
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, ...

New Lyme disease tests could offer quicker, more accurate detection

December 7, 2017
New tests to detect early Lyme disease - which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.

Spinal tap needle type impacts the risk of complications

December 6, 2017
The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by Hamilton medical researchers.

Men with HPV are 20 times more likely to be reinfected after one year

December 5, 2017
A new analysis of genital human papillomavirus (HPV) in men shows that infection with one HPV type strongly increases the risk of reinfection with the same type. In fact, men who are infected with the type responsible for ...

New tuberculosis drugs possible with understanding of old antibiotic

December 5, 2017
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and The Francis Crick Institute.

Scientists create successful mass production system for bioengineered livers

December 5, 2017
Researchers report creating a biologically accurate mass-production platform that overcomes major barriers to bioengineering human liver tissues suitable for therapeutic transplant into people.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.